drugset / Trial / NCT06760364
A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer
Phase 1
Recruiting
21 enrolled
Tianjin Medical University Cancer Institute and Hospital
Nanjing Calmhome Cell and Gene Engineering Institute Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
Evaluate the safety and efficacy of mesothelin-targeting UCAR-T cells in the treatment of mesothelin-positive advanced pancreatic cancer
Timeline
- Start
- 2024-12-25
- Primary completion
- 2027-12-24
- Completion
- 2039-12-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CHT102 | Cell therapy | — | Other |
Indications
No indication recorded.